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Introduction: 
L'étude proposée s'inscrit dans un projet appelé« La Mascota »qui a débuté en 1986. Il s'agit d'un programme 
de jumelage entre La Mascota - hôpital pédiatrique de Managua au Nicaragua, - et les hôpitaux de Monza et 
Milan en Italie et Bellinzona en Suisse. Dans notre étude, nous avons évalué la contribution de la caractérisation 
cytogénétique de la Leucémie Lymphoblastique Aigue (LLA) comme facteur pronostique comparée aux 
paramètres cliniques, morphologiques et immunohistochimiques. 
Méthode: 
Tous les patients avec une LLA, diagnostiquée et traitée dans le seul hôpital d'Oncologie Pédiatrique du 
Nicaragua en 2006, ont été étudié prospectivement. Le diagnostic de l'immunophénotype a été réalisé sur place, 
des échantillons de moelle osseuse ou de sang ont été envoyé au laboratoire de cytogénétique de Zürich pour des 
analyse caryotypique par G-banding et analyses d'hybridation fluorescente in Situ (FISH) à la recherche de 
marqueurs cytogénétiques de leucémie connus. 
Résultats: 
Soixante six patients avec une LLA ont été évalué. Leur âge moyen au diagnostique était de 7.3 ans, le 31.8% 
était 2::10 ans. Trente trois patients (51.5%) présentaient au diagnostic une hyperleucocytose 2::50 109/L, 45 
(68.2%) une hepatosplenomégalie. L'Immunophénotype a révélé dans 63/66 patients (95%) une LLA de type 
pré-B, 2 (3%) une LLA de type Tet 1 (1.5 %) une LLA de type B-mature. 
Les analyses du FISH ont démontré une fusion TELIAMLJ chez 9/66 patients(14%), la fusion BCRIABL chez 1 
patient (1.5%), un réarrangement MLL chez 2 patients (3.1%), un iAMP21 chez 2 patients (3.1%), un 
réarrangement MYC chez 1 patient (1.5%) et une hyperdiploïdie élevée chez 16 patients (24%). 
Tous les patients, à l'exception de 2, avec une fusion TEL/AMLJ et une hyperdiploïdie élevée étaient 
cliniquement et hématologiquement dans le groupe à risque standard. Par contre, ceux qui avaient des facteurs 
cytogénétiques de mauvais pronostic, avaient des caractéristiques cliniques du groupe à haut risque et étaient 
traités intensivement. 
Conclusions: 
Comparé à l'Europe, les enfants atteints de LLA au Nicaragua sont plus âgés, ont une proportion majeure de 
facteurs de mauvais pronostic clinique et hématologique et reçoivent un traitement plus intensif, tandis que les 
patients avec la translocation TELIAMLJ et avec une hyperdiploïdie élevée sont selon la clinique déjà dans le 
groupe à risque standard. Les résultats cytogénétiques n'ont pas contribué aux décisions thérapeutiques. Du 
point de vue coût-bénéfice, introduire de routine des analyses cytogénétiques pour la LLA ne semble pas une 
priorité par rapport à la nécessité de diagnostiquer plus précocement la maladie pour améliorer la compliance au 
traitement et la survie. 
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Background. Within the frame of a twinning programme with 
Nicaragua, The La Mascota project, we evaluated in our study the 
contribution of cytogenetic characterization of acute lymphoblastic 
leukemia (ALL) as prognostic factor compared to clinical, morpho-
logical, and immunohistochemical parameters. Methods. Ali 
patients with ALL treated at the only cancer pediatric hospital in 
Nicaragua during 2006 were studied prospectively. Diagnostic 
immunophenotyping was performed locally and bone marrow or 
blood samples were sent to the cytogenetic laboratory of Zurich for 
fluorescence in situ hybridization (FISH) analysis and G-banding. 
Results. Sixty-six patients with ALL were evaluated. Their mean 
age at diagnosis was 7.3 years, 31.8% were ::0:10 years. Thirty-four 
patients (51.5'Vo) presented with hyperleucocytosis ::0:50 x 109/L, 
45 (68.2%) had hepatosplenomegaly. lmmunophenotypically 63/66 
patients (95%) had a B-precursor, 2 (3%) a T- and 1 (1.5%) a 
B-mature ALL. FISH analysis demonstrated a TEL/AML 1 fusion in 
9/66 (14%), BCR/ABL fusion in 1 (1.5%), MLL rearrangement in 2 
(3.1 %), iAMP21 in 2 (3.1 %), MYC rearrangement in 1 (1.5%), and 
high-hyperdiploidy in 16 (24%). Ali patients but two with TEL/AML 1 
fusion and high-hyperdiploidy were clinically and hematologically 
in the standard risk group whereas those with poor cytogenetic 
factors had clinical high-risk features and were treated intensively. 
Conclusions. Compared to Europe, the ALL population in Nicaragua 
is older, has a higher proportion of poor prognostic clinical and 
hematological features and receives more intensive treatment, 
while patients with TEL/AML 1 translocations and high-hyperdiploidy 
are clinically in the standard risk group. Cytogenetics did not 
contribute as an additional prognostic factor in this setting. Pediatr 
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INTRODUCTION 
Acute Lymphoblastic Leukemia (ALL) is the most frequent type 
of childhood malignancy, representing one third of ail pediatric 
cancers. It is highly curable with an 80% cure rate in developed 
countries [!]. Whereas the incidence of childhood cancer in 
developing countries is comparable [2], outcome results are much 
lower especially for patients living in low-income countries [3-6]. 
Cure rate for ALL has been achieved through a better knowledge of 
risk factors and stratification of treatment according to risk groups 
[7,8], with reduced treatment intensity for patients with good 
prognostic factors and treatment intensification for those with 
adverse prognostic factors [9-13]. 
There is currently an initiative to reduce the mortality gap 
between childhood cancer in low-income and developed countries. 
Such a program exists in Nicaragua, the La Mascota Project. It 
started in 1986 at the La Mascota pediatric hospital in Managua, 
as a twinning project between the hospitals of Monza and Milan, 
Italy, and Bellinzona, Switzerland [14]. In the years following the 
introduction of the pro gram, the care of ALL patients in Nicaragua 
improved significantly and is offered now, free of charge, to ail 
Nicaraguan children with cancer [14]. Medical professionals 
(doctors, nurses, and laboratory technicians) were trained in the 
1980s and 1990s in Italy and Switzerland, and the immunopheno-
typing was introduced in the l 990s permitting more precise 
diagnosis of acute leukemias [15]. 
Although cytogenetic and molecular analyses of leukemic cells 
have significantly contributed to a better comprehension of the 
pathogenesis of childhood ALL [9, 10] and treatment adaptation and 
are routinely performed in developed countries, they have not yet 
been introduced in Nicaragua. 
The aim of the study was to prospectively perform a cytogenetic 
characterization of ALL in Nicaragua at diagnosis, to evaluate its 
contribution as prognostic factor by correlating the results with 
clinical, morphological and immunohistochemical parameters, and 
to compare them to Swiss and European data. 
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METHODS 
From January to December 2006, ail newly diagnosed 
patients with acute ALL in Nicaragua were included into the study. 
The study was performed in collaboration with the Pediatric 
Hematology-Oncology Unit of the University Hospital in Lausanne 
and the cytogenetic laboratory of the University Children's Hospital 
in Zurich, the Swiss referral centre for cytogenetic analysis in 
pediatric ALL. A physician trained in Switzerland spent 1 year in 
Nicaragua and was responsible for the collection of the clinical data 
at diagnosis, bone marrow aspiration, and preparation of sampi es for 
sending them to Switzerland. 
The diagnosis was performed locally by boue marrow aspiration, 
with analysis of morphology, cytochemistry (myeloperoxidase), 
and immunophenotype. For the latter the alkaline-phosphatase/ 
antialkaline-phosphatase (APAAP) method was used comprising 
CDIO, CD19, CD3, CD13, CD33, and CD45. 
Bone marrow aspiration or peripheral blood samples were 
cultured using a simplified published version of the method 
employed at the Zurich cytogenetic laboratory [16]. Cells were 
cultured in RPMI 1640 with Glutamax 1 (Invitrogen, Base!, 
Switzerland), supplemented with 20% fetal bovine serum 
(Invitrogen) and 1 % penicillin/streptomycin (Invitrogen). Colcemid 
(Invitrogen) was added prior to harvesting. The cells were fixed in 
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methanol 3: 1 acetic acid and were stored at -20°C. Once a month 
a batch of fixed cell preparations was sent by courier to the 
cytogenetic laboratory of the University Children's Hospital of 
Zurich where fluorescence in situ hybridization (FISH) analysis and 
G-banding were performed. 
For the FISH analysis the following probes were used: BCR/ 
ABL, TEL/AMLl, MLL (Abbott, Baar, Switzerland), and identi-
fication of high-hyperdiploidy. For cases with either confirmed or 
suspected T-ALL, a TLX3 probe was added (Dako, Baar, Switzer-
land) and for the only case with confirmed B-ALL, a MYC 
breakapart probe (Abbott) was used. 
Due to an intermittent unidentified problem with the quality of 
the preparations of heparinized bone marrow samples, EDTA (as a 
recommended substitute of heparin) samples were employed for 
the last 2 months, and did not influence the outcome of results [ 16]. 
The protocol was approved by both the Swiss and local ethics 
committees, and ail parents gave a written consent for cytogenetic 
analysis. 
RESULTS 
From January to December 2006, 71 children were diagnosed 
with ALL, 66 had complete clinical and laboratory data at diagnosis 
for evaluation summarized in Table I. Three patients were excluded 
because no BM was done or not enough material was available 
for cytogenetic analysis. In two other cases, diagnosis was 
undifferentiated leukemia. 
There were 37 females (56%) and 29 males (44%). The mean 
age at diagnosis was 7 .3 (SD ± 4.4) years. The risk distribution 
according to agecomprised 1 child (2%) < 1year,44 (66%) between 
1and10 years, and 21(32%)::;,10 years. Risk distribution according 
to blood cell counts revealed, a leukocyte count <50 x 109/L in 
45/66 (68%) patients, and a hyperleukocytosis ::0:50 x 109/L in 21 
(32%). Ten of the 21 patients had hyperleukocytosis > 100 x 109/L 
and 3 presented extreme levels of >400 x 109/L (10/21 patients= 
47%). Hepatosplenomegaly (HSM) (spleen or liver >2cm below 
costal margin assessed by physical examination) was present in 
45/66 (68%). 
The results of the immunophenotyping in 66 patients showed B-
progenitor ALL (CALLA, includingPre-B-ALL) in54 (81 %), and a 
T-cell immunophenotype in 2/66 (3%). There was only one patient 
TABLE 1. Patient Characteristics 
Features nb 
Total 66 
Gender 
Male 29 
Female 37 
Age (years) 
<l 1 
1<10 44 
~10 21 
Hepatosplenomegaly 
Yes 45 
No 21 
WBC (g/L) 
<10 30 
~10<50 15 
::;,50 21 
Range 
2-9 
10-16 
0.5-8.4 
16.6-48.9 
52.8-400 
Pediatr B/ood Cancer DOI 10.1002/pbc 
Median age (y) 
7 (2-16) 
6 (2-16) 
6 (1-15) 
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with B-mature ALL (2%). Nine patients showed Pro-BALL (14%) 
characteristics, derived from a very immature B-cell precursor. 
The cytogenetic results and their distribution by percentage are 
presented in Figure 1. 
Out of 66 patients, 9 (13%) showed a TEL/AMLl fusion. These 
patients had features of standard risk leukemia with a median age at 
diagnosis of 4 (2-12) years, with HSM in 6/9 (66%) and a median 
leukocyte count of 5.2 (3.3-91.3) x 109/L. A BCR/ABL fusion 
product was found in only one case (1.5%) in a patient who 
presented at diagnosis with hyperleukocytosis of 600 x 109/L 
concomitantly to a CNS infiltration. His leukemia expressed 
CDlO+, CD19+, and CD13+ and was classified as bi-phenotypic 
ALL. A MLL (1 lq23) rearrangement was identified in two patients 
(3.1 %). In the first case, a t(4;1 l) was seen in an infant with a 
hyperleukocytosis of 367 x 109/L at diagnosis and a pro-B ALL 
immunophenotype. The second patient was 6 years old, with a 
moderate hyperleukocytosis of 61. 7 x 109 /L at diagnosis and a pro-
B ALL immunophenotype. He later showed to be very resistant to 
treatment. Conventional cytogenetics showed a complex karyotype 
with an unidentified MLL partner chromosome. Signal pattern 
consistent with iAMP21 (amplification of AMLl) was found in two 
patients (3.1 %), who were ::0:6 years old and had a leukocyte count 
between 10 and 50 x 109/L. 
High-hyperdiploidy (51-67 chromosomes) was confirmed by 
conventional cytogenetics in 11 cases, and inferred in another 
5 based on FISH results, for a total of 16 patients (24%). The mean 
age of the subgroup high-hyperdiploidy was 3.5 (2-8) years and the 
mean leukocyte count at diagnosis 4.3 (1.1-52.8) x 109/L. The only 
patient with mature B-cell ALL, and morphologie FAB L3 criteria, 
also had cytogenetic confirmation of a MYC (8q24) rearrangement. 
The comparison of distribution of age, incidence of TEL/ AML 
and high-hyperdiploidy between ALL patients in Nicaragua and 
Switzerland is summarized in Table II. 
DISCUSSION 
The population of Nicaragua is 5.4 million people with 
approximately 49% of the population under the age of 18 years. 
The country has a yearly income per capita of 420 U.S. dollars. 
Manuel de Jesus Rivera La Mascota Children's Hospital in 
No 11bcmdions 
27% 
Otlwrs nbccratinns 
2H~ 
BCR-ABL 
l(9;22) 
1.5% 
c-MYC 
1(8;14) MJ.l, nmmmgçnu::.nt 
1.5% 3% 
TEL-AMLl 
t(l2;21) 
1T% 
Fig. 1. The distribution by percentage of the cytogenetic results. 
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TABLE II. Incidence of TEL/AMLl Fusion and H-H According to Age Group in Switzerland and Nicaragua 
Age distribution TEL/AMLl High-hyperdiploidy 
Nicaragua Switzerland Nicaragua Switzerland" Nicaragua Switzerland 
Age (y) No. % No. % No. % No. % No. % No. % 
Infant <l 1 1.5 10 2 0 0 0 0 0 0 0 0 
1 to <10 44 66.5 388 76 7 16 86 29 16 36.5 114 29.5 
>10 21 32 112 22 2 9.5 7 8.4 0 0 15 13.5 
Fisher t P=0.06 P=0.2 P=0.3 
"Numbers based on a consecutive series of 376 patients where TEL/AMLl was routinely tested. 
Managua, the capital city, is the only national centre for pediatric 
oncology, to where children are referred, diagnosed, and treated 
[17]. 
The yearly incidence of ALL in Nicaragua corresponds to 
formerly published data (30 cases per million children per year) on 
countries of Central America [15,18]. Surprisingly we observed a 
higher percentage of aider children (32%) compared to developed 
countries (20%) [2] whereas the incidence of very young patients 
<1 year of age was equally small (1.5%). Therefore, only 67% 
fulfilled criteria of favorable risk factors by age (1-10 years), a 
phenomenon also observed by others [5,6,15]. There was a female 
predominance (56%) in contrast to the usually observed male 
predominance [l]. 
The incidence of HSM was high with 68% (45/66 patients) in 
comparison with European data (30-50%) [19] and may be related 
to delayed diagnosis. Malta et al. [15] made a similar observation in 
1996, when the y found an incidence of HSM of 70% in Nicaraguan 
ALL patients. Among the 66 study patients, 21 had a hyper-
leukocytosis at diagnosis. Other three patients who had more than 
300 x 109/L leukocytes had either a T-ALL (one patient) or adverse 
cytogenetic factors such as MLL rearrangement (one patient) or 
t(9;22) (one patient). 
The incidence of B-progenitor ALL (81 % ) was very similar to 
that in Europe [20]. In contrast, T-ALL was found only in two 
patients (3% ), which appears Jess compared to international 
results, where approximately 10-15% of children present a T-cell 
immunophenotype [l]. T-ALL might also be under diagnosed in 
Nicaragua as only the surface marker CD3 (and not the cytoplasmic 
CD3) is available to diagnose T-lineage lymphoblasts. Conse-
quently some patients diagnosed as B-progenitor orundifferentiated 
ALL with clinical characteristics of a T-ALL might have been 
wrongly diagnosed. 
The cytogenetic mutations observed in Swiss patients with ALL 
are representative of Europe [21]. Therefore, main cytogenetic 
characteristics were compared to this population. The incidence 
of the TEL/AMLl fusion (13%) was not statistically different 
(P = 0.2), than the 22% reported in Switzerland (Table Il). The 
observed trend, however, might be explained by the smaller patient 
number studied compared to the Swiss cohort. Another explanation 
may Jay in the different age distribution of ALL patients in 
Nicaragua. TEL/AMLl patients have a classical prevalence in the 
< 10 years age group. In the studied patient population, 32 % of 
patients were aider than 10 years of age, which is a higher proportion 
than usually observed [7]. These patients also had more often HSM 
and hyperleukocytosis than patients in developed countries (31/44 
patients (70%) < 10 years had HSM and 14/21(66%)>10 years had 
Pediatr Blood Cancer DOI 10.1002/pbc 
HSM) [ 15]. Thus, the low incidence and poor outcome of the TEL/ 
AMLl fusion appears to be real in Nicaragua. It is similar to what 
has been found in people of Hispanie origin living in the U.S.A., 
where an incidence of 13% ofTEL/AMLl fusion has been reported 
by Aldrich et al. [22] and might reflect a racial difference of the 
disease. Among the patients with the TEL/AMLI translocation, 
only two out of nine patients were aider than 10 years and treated 
with more intensive chemotherapy. A further interesting observa-
tion is the under representation of high-hyperdiploidy in ALL. This 
result is similar as for TEL/AMLl mutation, when considering the 
different age distribution of ALL, which again showed only a trend 
without reaching statistically significance (P = 0.3). 
The incidence of adverse prognostic factors such as MLL 
rearrangement or t(9;22) was very low as observed elsewhere [l]. 
These patients fulfilled clinical high-risk criteria at presentation 
with hyperleukocytosis, HSM, age < 1 or > 10 years, and more 
intensive therapy. 
Only three reports are available in the medical literature 
regarding cytogenetic analysis in children with ALL in developing 
countries. The studies of Macedo et al. [23] from Rio de Janeiro, 
Pérez-Vera et al. [24] from Mexico City, and Chang et al. [25] from 
Taiwan are ail institutional studies; they describe the frequency of 
the chromosomal abnormalities in ALL patients without making 
any correlation with clinical risk factors. 
In conclusion, cytogenetic analyses of ALL in Nicaragua 
showed a slightly different distribution than that observed in 
Western countries with a smaller proportion of favorable risk factors 
such as TEL/AMLl and high-hyperdiploidy. These results corre-
lated well with a higher proportion of a clinical high-risk population 
by older age, hyperleukocytosis, and tumor volume by HSM 
receiving high-risk treatment. On the other hand, ail patients with 
hyperdiploidy and 7 /9 patients with TEL/ AMLl were already in 
the favorable treatment-group according to age and were treated 
as standard risk patients. Thus, the cytogenetic results did not 
contribute to therapeutic decision. From the cost-benefit point of 
view, introducing routine cytogenetic analysis for ALL seems not to 
be a priority in this setting compared to needs of early referral, 
treatment compliance, and follow-up. There are needs to focus 
financial support on improvement of basic laboratory facilities and 
training of non-hospital physicians for timely referral of children 
for further investigation, on improvement of supportive care and 
hospital facilities, and on expansion of the existing immunopheno-
typing for more precise diagnosis of ALL and follow-up. In a second 
step, introducing a routine FISH analysis in order to allow for better 
stratification within the HR and LR patient groups in order to change 
treatment approaches. 
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